{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:21:30Z","timestamp":1760242890060,"version":"build-2065373602"},"reference-count":36,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T00:00:00Z","timestamp":1477526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Veterinary Sciences"],"abstract":"<jats:p>Type I interferons (IFNs) are well-known cytokines that, among their main functions, are key components of the host immune response against viral infections. Due to its immune modulation properties, they are commonly used in the therapeutic approach of various retroviral infections, namely human immunodeficiency virus (HIV) and feline immunodeficiency virus (FIV). In HIV infection, it has been shown that IFN therapy limits early viral replication, particularly useful on post-exposure prophylaxis. In veterinary medicine, recombinant feline interferon omega (rFeIFN-\u03c9) was the first interferon licensed for use in cats. Several studies have recently shown that this compound seems to stimulate the innate immunity, decreasing clinical signs and co-infections in naturally FIV-infected cats. More than summarizing the main conclusions about rFeIFN-\u03c9 in cats, this review emphasizes the immune-modulation properties of IFN therapy, opening new perspectives for its use in retroviral infections. Either in FIV-infected cats or in HIV individuals, type I IFNs seem to induce an innate immune-modulation and should not be overlooked as a therapeutic option in retroviral infections.<\/jats:p>","DOI":"10.3390\/vetsci3040032","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T10:17:52Z","timestamp":1477563472000},"page":"32","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Use of Recombinant Feline Interferon Omega Therapy as an Immune-Modulator in Cats Naturally Infected with Feline Immunodeficiency Virus: New Perspectives"],"prefix":"10.3390","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2463-4062","authenticated-orcid":false,"given":"Rodolfo","family":"Leal","sequence":"first","affiliation":[{"name":"Centre Hospitalier V\u00e9t\u00e9rinaire Fregis, 43 Av. Aristide Briand, Arcueil 94110, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9565-6261","authenticated-orcid":false,"given":"Solange","family":"Gil","sequence":"additional","affiliation":[{"name":"Centro de Investiga\u00e7\u00e3o Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina, Veterin\u00e1ria, University of Lisbon (ULisbon), Av. Universidade T\u00e9cnica, Lisbon 1300-477, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2016,10,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.3390\/v4112684","article-title":"Clinical aspects of feline retroviruses: A review","volume":"4","author":"Hartmann","year":"2012","journal-title":"Viruses"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.vetimm.2011.06.003","article-title":"Clinical aspects of feline immunodeficiency and feline leukemia virus infection","volume":"143","author":"Hartmann","year":"2011","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/1098612X15610676","article-title":"Efficacy of antiviral chemotherapy for retrovirus-infected cats: What does the current literature tell us?","volume":"17","author":"Hartmann","year":"2015","journal-title":"J. Feline Med. Surg."},{"key":"ref_4","unstructured":"Hartmann, K. (2012). Infectious Diseases of the Dog and Cat, Elsevier."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri2314","article-title":"Interferon-inducible antiviral effectors","volume":"8","author":"Sadler","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.4049\/jimmunol.174.4.1932","article-title":"IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29","volume":"174","author":"Pirhonen","year":"2005","journal-title":"J. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/ni1141","article-title":"Plasmacytoid dendritic cells in immunity","volume":"5","author":"Colonna","year":"2004","journal-title":"Nat. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2460\/ajvr.67.6.1025","article-title":"Activity of feline interferon-omega after ocular or oral administration in cats as indicated by Mx protein expression in conjunctival and white blood cells","volume":"67","author":"Bracklein","year":"2006","journal-title":"Am. J. Vet. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1099\/0022-1317-81-10-2341","article-title":"Interferons: Cell signalling, immune modulation, antiviral response and virus countermeasures","volume":"81","author":"Goodbourn","year":"2000","journal-title":"J. Gen. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/nature13554","article-title":"Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression","volume":"511","author":"Sandler","year":"2014","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nrmicro3449","article-title":"HIV-1 and interferons: Who\u2019s interfering with whom?","volume":"13","author":"Doyle","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1099\/vir.0.83530-0","article-title":"APOBEC3G upregulation by alpha interferon restricts human immunodeficiency virus type 1 infection in human peripheral plasmacytoid dendritic cells","volume":"89","author":"Wang","year":"2008","journal-title":"J. Gen. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00002030-198903010-00006","article-title":"HIV replication can be blocked by recombinant human interferon beta","volume":"3","author":"Michaelis","year":"1989","journal-title":"AIDS Lond. Engl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1086\/655971","article-title":"Cohorts for the study of HIV-1-exposed but uninfected individuals: Benefits and limitations","volume":"202","author":"Horton","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_15","first-page":"43","article-title":"Interferon responses in HIV infection: From protection to disease","volume":"16","author":"Sivro","year":"2014","journal-title":"AIDS Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/infdis\/jis663","article-title":"Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration","volume":"207","author":"Azzoni","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.vetimm.2011.06.008","article-title":"Use of recombinant interferon omega in feline retrovirosis: From theory to practice","volume":"143","author":"Collado","year":"2011","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_18","first-page":"477","article-title":"Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV\/feline immunodeficiency virus (FIV)-coinfected symptomatic cats","volume":"18","author":"Maynard","year":"2004","journal-title":"J. Vet. Intern. Med. Am. Coll. Vet. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1089\/107999099313325","article-title":"Immunomodulation and therapeutic effects of the oral use of interferon-alpha: Mechanism of action","volume":"19","author":"Tompkins","year":"1999","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1128\/AAC.28.5.698","article-title":"Susceptibility of feline herpesvirus 1 and a feline calicivirus to feline interferon and recombinant human leukocyte interferons","volume":"28","author":"Fulton","year":"1985","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.vetimm.2005.08.020","article-title":"Low-dose interferon-alpha treatment for feline immunodeficiency virus infection","volume":"109","author":"Pedretti","year":"2006","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0378-1135(89)90049-7","article-title":"Inhibitory effects of ribavirin alone or combined with human alpha interferon on feline infectious peritonitis virus replication in vitro","volume":"20","author":"Weiss","year":"1989","journal-title":"Vet. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1128\/AAC.34.9.1749","article-title":"Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome","volume":"34","author":"Zeidner","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","first-page":"862","article-title":"Antiviral potency of interferon omega against selected canine and feline viruses","volume":"83","author":"Truyen","year":"2002","journal-title":"Der. Praktische Tierarzt"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.rvsc.2013.11.007","article-title":"Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats: Clinical and laboratory evaluation","volume":"96","author":"Gil","year":"2014","journal-title":"Res. Vet. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.rvsc.2012.09.025","article-title":"Relevance of feline interferon omega for clinical improvement and reduction of concurrent viral excretion in retrovirus infected cats from a rescue shelter","volume":"94","author":"Gil","year":"2013","journal-title":"Res. Vet. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.rvsc.2015.02.008","article-title":"Evaluation of viremia, proviral load and cytokine profile in naturally feline immunodeficiency virus infected cats treated with two different protocols of recombinant feline interferon omega","volume":"99","author":"Leal","year":"2015","journal-title":"Res. Vet. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jsap.12160","article-title":"Monitoring acute phase proteins in retrovirus infected cats undergoing feline interferon-\u03c9 therapy","volume":"55","author":"Leal","year":"2014","journal-title":"J. Small Anim. Pract."},{"key":"ref_29","first-page":"E1092","article-title":"The acute-phase protein response to human immunodeficiency virus infection in human subjects","volume":"276","author":"Jahoor","year":"1999","journal-title":"Am. J. Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1590\/S1413-86702001000400005","article-title":"Lipid and acute-phase protein alterations in HIV-1 infected patients in the early stages of infection: Correlation with CD4+ lymphocytes","volume":"5","author":"Treitinger","year":"2001","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2249.2010.04145.x","article-title":"Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment","volume":"161","author":"Barbai","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jfms.2009.05.006","article-title":"Feline immunodeficiency. ABCD guidelines on prevention and management","volume":"11","author":"Hosie","year":"2009","journal-title":"J. Feline Med. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1939-165X.2005.tb00019.x","article-title":"Acute phase proteins in dogs and cats: Current knowledge and future perspectives","volume":"34","author":"Ceron","year":"2005","journal-title":"Vet. Clin. Pathol. Am. Soc. Vet. Clin. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tvjl.2007.06.005","article-title":"The feline acute phase reaction","volume":"177","author":"Paltrinieri","year":"2008","journal-title":"Vet. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.vetimm.2011.06.005","article-title":"The innate antiviral immune system of the cat: Molecular tools for the measurement of its state of activation","volume":"143","author":"Cattori","year":"2011","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jfms.2011.05.012","article-title":"Comparative efficacy of a recombinant feline interferon omega in refractory cases of calicivirus-positive cats with caudal stomatitis: A randomised, multi-centre, controlled, double-blind study in 39 cats","volume":"13","author":"Hennet","year":"2011","journal-title":"J. Feline Med. Surg."}],"container-title":["Veterinary Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2306-7381\/3\/4\/32\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:34:05Z","timestamp":1760211245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2306-7381\/3\/4\/32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,27]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,12]]}},"alternative-id":["vetsci3040032"],"URL":"https:\/\/doi.org\/10.3390\/vetsci3040032","relation":{},"ISSN":["2306-7381"],"issn-type":[{"type":"electronic","value":"2306-7381"}],"subject":[],"published":{"date-parts":[[2016,10,27]]}}}